PaxVax to Receive California Life Sciences Association's 2016 Rising Star Award
REDWOOD CITY, Calif., Oct. 11, 2016 /PRNewswire/ -- PaxVax, Inc., a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases, today announced that it has been selected to receive the 2016 DiNA™ Rising Star Award from the California Life Sciences Association (CLSA) at its annual Pantheon Awards Ceremony, which honors innovation and excellence within California's life sciences sector. The awards program, now in its 13th year, will take place on Friday, December 2 in San Francisco, CA.
"We're proud to be honored by the California Life Sciences Association and receive the Pantheon DiNA Rising Star Award, and to be recognized alongside some of the most distinguished leaders in the life sciences industry," said Nima Farzan, President and CEO of PaxVax. "At PaxVax, each day we are inspired by these leaders and many others, as we work to develop innovative vaccines that address significant gaps in preventative health."
PaxVax has extensive research and development capabilities, a world-class manufacturing facility and an on-the-ground sales presence in the U.S. and across Europe. In June 2016, PaxVax received approval from the United States Food and Drug Administration (FDA) for the cholera vaccine Vaxchora™. In July of 2014, PaxVax acquired the FDA-approved typhoid vaccine Vivotif® from Crucell Switzerland AG. Currently, PaxVax's robust pipeline includes vaccines at various stages of research and clinical development for adenovirus, anthrax, hepatitis A, HIV, and Zika.
About PaxVax
PaxVax develops, manufactures and commercializes innovative specialty vaccines against infectious diseases present and emerging in the developing world. PaxVax has licensed vaccines for typhoid fever (Vivotif®) and cholera (Vaxchora™), and vaccines at various stages of research and clinical development for adenovirus, anthrax, hepatitis A, HIV, and Zika. PaxVax is focused on traditionally overlooked markets such as travel, and as part of its social mission, PaxVax is also working to make its vaccines available to broader populations most affected by these diseases. PaxVax is headquartered in Redwood City, California and maintains research and development and Good Manufacturing Practice (GMP) facilities in San Diego, California and Bern, Switzerland and other operations in Bermuda and Europe. More information is available at www.PaxVax.com.
About California Life Sciences Association (CLSA)
California Life Sciences Association (CLSA) is the state's largest and most influential life sciences advocacy and business leadership organization. With offices in Sacramento, San Diego, South San Francisco, Los Angeles and Washington DC, CLSA works closely with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device and diagnostics companies, research universities and institutes, investors and service providers throughout the Golden State. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged. Visit CLSA at www.califesciences.org and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn and YouTube.
SOURCE PaxVax, Inc.
Share this article